These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29158470)

  • 1. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.
    Naik S; Galyon GD; Jenks NJ; Steele MB; Miller AC; Allstadt SD; Suksanpaisan L; Peng KW; Federspiel MJ; Russell SJ; LeBlanc AK
    Mol Cancer Ther; 2018 Jan; 17(1):316-326. PubMed ID: 29158470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
    LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
    Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
    Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
    Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
    Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review.
    Moglan AM; Albaradie OA; Alsayegh FF; Alharbi HM; Samman YM; Jalal MM; Saeedi NH; Mahmoud AB; Alkayyal AA
    Front Immunol; 2023; 14():1085940. PubMed ID: 37063914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
    Cook J; Peng KW; Witzig TE; Broski SM; Villasboas JC; Paludo J; Patnaik M; Rajkumar V; Dispenzieri A; Leung N; Buadi F; Bennani N; Ansell SM; Zhang L; Packiriswamy N; Balakrishnan B; Brunton B; Giers M; Ginos B; Dueck AC; Geyer S; Gertz MA; Warsame R; Go RS; Hayman SR; Dingli D; Kumar S; Bergsagel L; Munoz JL; Gonsalves W; Kourelis T; Muchtar E; Kapoor P; Kyle RA; Lin Y; Siddiqui M; Fonder A; Hobbs M; Hwa L; Naik S; Russell SJ; Lacy MQ
    Blood Adv; 2022 Jun; 6(11):3268-3279. PubMed ID: 35175355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma.
    Makielski KM; Sarver AL; Henson MS; Stuebner KM; Borgatti A; Suksanpaisan L; Preusser C; Tabaran AF; Cornax I; O'Sullivan MG; Chehadeh A; Groschen D; Bergsrud K; Pracht S; Winter A; Mills LJ; Schwabenlander MD; Wolfe M; Farrar MA; Cutter GR; Koopmeiners JS; Russell SJ; Modiano JF; Naik S
    Mol Ther Oncolytics; 2023 Dec; 31():100736. PubMed ID: 37965295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
    Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
    Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
    Betancourt D; Ramos JC; Barber GN
    J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma.
    Makielski KM; Sarver AL; Henson MS; Stuebner KM; Borgatti A; Suksanpaisan L; Preusser C; Tabaran AF; Cornax I; O'Sullivan MG; Chehadeh A; Groschen D; Bergsrud K; Pracht S; Winter A; Mills LJ; Schwabenlander MD; Wolfe M; Farrar MA; Cutter GR; Koopmeiners JS; Russell SJ; Modiano JF; Naik S
    bioRxiv; 2023 Sep; ():. PubMed ID: 37131624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
    Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
    Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Preclinical Models of Non-Small Cell Lung Cancer.
    Patel MR; Jacobson BA; Ji Y; Hebbel RP; Kratzke RA
    Transl Oncol; 2020 Jul; 13(7):100782. PubMed ID: 32422574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.
    Cejalvo T; Perisé-Barrios AJ; Del Portillo I; Laborda E; Rodriguez-Milla MA; Cubillo I; Vázquez F; Sardón D; Ramirez M; Alemany R; Del Castillo N; García-Castro J
    Cancer Res; 2018 Sep; 78(17):4891-4901. PubMed ID: 29991502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
    Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
    Hastie E; Grdzelishvili VZ
    J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.